The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2025 | A US perspective on conditioning regimens in stem cell transplantation for AML and MDS
In this video, Filippo Milano, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA, provides a US perspective on conditioning regimens in stem cell transplantation (SCT) for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), highlighting that the increased use of post-transplant cyclophosphamide (PTCy) for graft-versus-disease (GvHD) prophylaxis has significantly impacted the transplant landscape. This interview took place at the 51st Annual Meeting of the EBMT in Florence, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So in my session I spoke about the landscape of conditioning regimens in the United States. The main factor is that really the use of post-transplant cyclophosphamide for GVHD prophylaxis has changed the impact of the conditioning regimens and what we use in the United States. For example, the use of reduced intensity conditioning regimens like Fludara is increasing, while the use of other regimens like busulfan and cyclophosphamide is definitely less used than before because of the use of PTCy as a GVHD prophylaxis...
So in my session I spoke about the landscape of conditioning regimens in the United States. The main factor is that really the use of post-transplant cyclophosphamide for GVHD prophylaxis has changed the impact of the conditioning regimens and what we use in the United States. For example, the use of reduced intensity conditioning regimens like Fludara is increasing, while the use of other regimens like busulfan and cyclophosphamide is definitely less used than before because of the use of PTCy as a GVHD prophylaxis. The main takeaways of my session were definitely that the landscape has changed and that has really opened the options for different stem cell sources. As I showed in my session, the number of mismatched unrelated transplants has increased over the years and that is definitely showing the impact that PTCy has had on transplant activity in the United States, especially for patients with AML and MDS.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
